The SPES Radioactive Ion Beam (RIB) facility at INFN-LNL is in the construction phase. It is based on the ISOL method with an UCx Direct Target able to sustain a power of 10 kW. The primary proton beam is delivered by a high current Cyclotron accelerator, with energy 35-70 MeV and a beam current of 0.2-0.5 mA. Neutron-rich radioactive ions will be produced by proton induced Uranium fission in the UCx target at an expected fission rate in the order of 1013 fissions per second. The exotic isotopes will be re-accelerated by the ALPI superconducting LINAC at energies of 10A MeV and higher, for masses in the region A=130 amu at expected rate on the secondary target of 107 – 109 pps. The SPES project has the aim to provide high intensity and highquality beams of neutron-rich nuclei as well as to develop an interdisciplinary research center based on the cyclotron proton beam.

Radio Pharmaceutical Therapy (RPT) comes forth as a promising technique to treat a wide range of tumors while ensuring low collateral damage to nearby healthy tissues. This kind of cancer therapy exploits the radiation following the decay of a specific radionuclide to deliver a lethal dose to tumor tissues. In the framework of the ISOLPHARM project of INFN, ¹¹¹Ag was recently proposed as a promising core of a therapeutic radiopharmaceutical. In this paper, the production of ¹¹¹Ag via neutron activation of ¹¹⁰Pd-enriched samples inside a TRIGA Mark II nuclear research reactor is studied. The radioisotope production is modeled using two different Monte Carlo codes (MCNPX and PHITS) and a stand-alone inventory calculation code FISPACT-II, with different cross section data libraries. The whole process is simulated starting from an MCNP6-based reactor model producing the neutron spectrum and flux in the selected irradiation facility. Moreover, a cost-effective, robust and easy-to-use spectroscopic system, based on a Lanthanum Bromo-Chloride (LBC) inorganic scintillator, is designed and characterized, with the aim of using it, in the future, for the quality control of the ISOLPHARM irradiated targets at the SPES facility of the Legnaro National Laboratories of INFN. ^natPd and ¹¹⁰Pd-enriched samples are irradiated in the reactor main irradiation facility and spectroscopically characterized using the LBC-based setup and a multiple-fit analysis procedure. Experimental results are compared with theoretical predictions of the developed models, showing that inaccuracies in the available cross section libraries prevent an accurate reproduction of the generated radioisotope activities. Nevertheless, models are normalized to our experimental data allowing for a reliable planning of the ¹¹¹Ag production in a TRIGA Mark II reactor.

The ISOLPHARM (ISOL technique for radioPHARMaceuticals) project is dedicated to the development of high purity radiopharmaceuticals exploiting the radionuclides producible with the future Selective Production of Exotic Species (SPES) Isotope Separation On-Line (ISOL) facility at the Legnaro National Laboratories of the Italian National Institute for Nuclear Physics (INFN-LNL). At SPES, a proton beam (up to 70 MeV) extracted from a cyclotron will directly impinge a primary target, where the produced isotopes are released thanks to the high working temperatures (2000 °C), ionized, extracted and accelerated, and finally, after mass separation, only the desired nuclei are collected on a secondary target, free from isotopic contaminants that decrease their specific activity. A case study for such project is the evaluation of the feasibility of the ISOL production of ⁶⁴Cu and ⁶⁷Cu using a zirconium germanide target, currently under development. The producible activities of ⁶⁴Cu and ⁶⁷Cu were calculated by means of the Monte Carlo code FLUKA, whereas dedicated off-line tests with stable beams were performed at LNL to evaluate the capability to ionize and recover isotopically pure copper.